Podcasts about Io

''L'età è solo un numero''. Questo ha detto un chatbot IA a una 14enne. Altri bot sono collegati a suicidi di minori. La risposta delle Big Tech? ''Li usate male'', scaricando la colpa e invocando la ''libertà di parola'' per un software.Ma questa non è una falla: è negligenza progettuale. È la Silicon Valley che passa dal ''rompere le cose'' al ''rompere i ragazzini''. L'IA non è neutrale e questa implementazione sconsiderata, guidata solo dal profitto, è un esperimento sociale non regolamentato sui nostri figli.Di chi è davvero la colpa? ~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Dopo esserci occupati dell'Iniziativa per il futuro, diamo spazio all'altro oggetto in votazione a livello federale a fine mese: l'iniziativa popolare denominata “Per una Svizzera che si impegna” (l'Iniziativa Servizio civico). Il testo propone una vera e proprio riforma: introdurre un obbligo di servire per tutti, uomini e donne, un servizio di milizia riconosciuto sul modello di quello militare, da svolgere non necessariamente nell'esercito, ma a favore della collettività, in ambito sociale, sanitario o ambientale per esempio. In questo modo si favorirebbe la coesione sociale e si garantirebbe un'uguaglianza di trattamento, di doveri e di opportunità a donne e uomini. All'esercito e alla protezione civile verrebbero comunque garantiti gli effettivi necessari per funzionare. E' un'iniziativa promossa da numerosi politici provenienti da praticamente tutti i partiti, anche da donne di sinistra, e ha il sostegno anche di militari, oltre che di rappresentanti della società civile. Ma per il Consiglio federale e per la maggioranza del Parlamento va troppo oltre. Ne risulterebbero soprattutto costi elevati per la Confederazione e i Cantoni, e anche l'economia ne risentirebbe in modo significativo. Un servizio civico promuove veramente l'uguaglianza o penalizza ulteriormente le donne? Indebolisce l'esercito o militarizza la società? Favorisce l'impegno di ognuno a favore della collettività oppure introduce un volontariato forzato in ambiti già mal retribuiti?Ne discuteremo conJonathan Binaghi, ufficiale ed ex guardia pontificia, del Comitato d'iniziativa Barbara Di Marco Christoffel, del collettivo “Io l'8”Michele Moor, presidente della Società svizzera degli ufficiali, membro dell'Alleanza sicurezza svizzeraCamilla Tartaglia, dei giovani Verdi liberali

It's all rhymes and good times in this very special episode of Chat Scene! MC Hammersmith (aka our dear friend Will Naameh) is back again, this time discussing his origins in comedy and hip-hop, and giving us some advanced tips and tricks on rhyming. Join us! --- MC Hammersmith (the alias of Will Naameh), is a multi-award winning hip hop comedian.
He is the world's leading rapper to ever emerge from the ghetto of middle class west London. In his live shows, MC Hammersmith performs improvised hip hop comedy. The lyrics and rhymes of his raps are 100% improvised and based entirely on audience suggestions. In this guise he has won numerous comedy awards, headlined weekends at every major comedy club in the UK, sold out multiple consecutive runs at the Edinburgh Fringe Festival, supported Jason Manford on his live arena tour, and is currently on his third nationwide solo tour. He also writes and performs scripted hip hop comedy tracks, which have gone viral on numerous platforms – most notably racking up over 100 million views on TikTok. He has over 1M followers across social media. He has performed alongside famous hip hop and rap artists – most notably rapping for Dave in a viral “Guess The Musician” Beta Squad video, and being invited to freestyle at R.A. The Rugged Man's London live show. He is also a writer for acclaimed YouTube series Epic Rap Battles of History. Having started comedy as an improvisational comedian, he trained at Second City Chicago, iO, Annoyance, and UCB New York. He still performs improv today, in some of the world's biggest touring improv shows – he can frequently be spotted improvising with Baby Wants Candy, Shamilton, and The Spontaneous Players at the Edinburgh Fringe Festival and across the globe. He has headlined numerous international improv festivals, and was the first person in the UK to perform improv in an arena. @mc_hammersmith Cast: Lily Ludwig, Austin Packard, MC Hammersmith Music Director: Sam Scheidler Drums: Chris Ditton Follow us @CharmScenePod on Instagram, TikTok, and YouTube, join our Discord, or shoot us a message at CharmScenePod@gmail.com!

Are you losing deals because you hate follow-up? In this episode, Chad sits down with Jordan Fleming, co-founder of Smartphone, to bridge the gap between high-tech automation and genuine human connection. Jordan reveals why teaching "skills over scripts" leads to better rapport with sellers and how AI voice agents are evolving from simple tools into a 24/7 labor force.We dive deep into:Why the "money is in the follow-up" is more than just a cliché—and how to automate it without losing the personal touch.The massive shift from "cold calling" to "warm transfers" using AI.Why empathy wins deals: Moving from transactional scripts to "Are you okay?"How to leverage Smartphone to integrate your communications directly with your CRM.Plus, Jordan shares a mind-blowing story about an AI agent showing empathy that you have to hear to believe. If you want to scale your business while reclaiming your freedom, this episode is a must-listen.Jordan is offering a free copy of his book here: Click. Call. Scale.You can also learn more about Jordan on his Instagram and SmrtPhone.IO.Connect with Chad on LinkedIn⁠⁠Follow Chad on Instagram⁠⁠Follow Chad on YouTube⁠⁠Follow True Wealth on Facebook⁠Be sure to leave a rating & review to let us know how this show has helped YOU!Visit our website at ⁠⁠www.TrueWealthInvestors.com⁠⁠ for more real estate wisdom and resources.

In 2000, Hitman: Codename 47 introduced players to Agent 47 and a new breed of stealth gaming built on improvisation, experimentation, and precision. In this episode, we trace how a small team of Danish demoscene veterans formed IO Interactive, built the Glacier Engine from scratch, and turned a 'simple shooter' concept into one of the most influential stealth franchises in history. We follow the evolution from Codename 47's experimental beginnings to Silent Assassin's refinement and Contracts' atmospheric retelling, exploring how each installment shaped IO's design philosophy. Our conversation also touches on IO's roots, ragdoll physics innovation, and the World of Assassination era that followed. Join us as we slip into the shadows and revisit Hitman's origin story on today's trip down Memory Card Lane.Read transcript

Et si la naturopathie pouvait devenir votre alliée pour mieux vivre votre parcours de PMA ?

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

Dell Technologies has unveiled enhancements to the Dell AI Factory designed to simplify and accelerate the enterprise AI journey. These portfolio additions boost performance and automation for AI workloads while removing bottlenecks, delivering greater control with integrated, resilient on-premises infrastructure. Why it matters In today's digital landscape, organisations increasingly rely on AI to stay competitive and foster innovation. The momentum is clear with 85 percent of enterprises planning to move AI on-premises within the next 24 months. Seventy-seven per cent of those seeking AI are looking for one holistic infrastructure vendor to provide capabilities across their AI journey. Dell's expanded portfolio addresses these needs with the industry's broadest end-to-end AI portfolio designed to streamline AI adoption and deliver impactful results. Simplified and automated AI journey The Dell Automation Platform, now expanded to the Dell AI Factory, will deliver smarter, more automated experiences by deploying validated, optimised solutions with a secure framework. This approach will produce repeatable outcomes, eliminate guesswork, and help unlock the full potential of AI-driven use cases across Dell's ecosystem of technology partners. Key advancements include: Software-driven tools like the AI code assistant with Tabnine and agentic AI platform with Cohere North are now automated, getting AI workloads into production faster, streamlining operations and enhancing scalability. Dell Professional Services provide turnkey interactive AI use case pilots using real customer data to validate business value ahead of scaled investments. These expert-led pilots offer a hands-on preview for experimentation with clear success metrics and KPIs, delivering tangible ROI. Breakthrough performance and efficiency for AI workloads Enhanced Data Management: How organisations manage, secure and scale that data will separate the winners from the laggards. Updates to Dell PowerScale and Dell ObjectScale, the Dell AI Data Platform's storage engines, boost performance, scalability, and data discovery capabilities. Dell PowerScale will soon be available as an independent software license on qualified Dell PowerEdge servers like the Dell PowerEdge R7725xd. This news is the latest in Dell software-driven storage innovation following the announcement of a new software-defined Dell ObjectScale. These new Dell PowerScale and Dell ObjectScale configurations will help organisations like cloud service providers realise even greater AI performance while having the flexibility to adopt the latest server and networking technologies to meet infrastructure needs. Dell PowerScale parallel NFS (pNFS) support with Flexible File Layout will enable two-way communication between the metadata server and client, allowing for better parallel distribution of data across multiple nodes in a PowerScale cluster. Deliver significant throughput, performance gains and linear scalability with parallel I/O across multiple pathways. This update is designed to provide increased parallelism, delivering massive scalability and throughput tailored for demanding AI workflows. Dell ObjectScale AI-Optimised Search offers two complementary AI-optimised search capabilities for Dell ObjectScale storage - S3 Tables and S3 Vector. These two specialised APIs provide high-speed access to complex data stored directly on ObjectScale to support analytics and key AI workloads like inferencing and retrieval-augmented generation (RAG), empowering faster decision-making and easier storage, retrieval and search of expanding datasets. PowerEdge Innovations: Dell PowerEdge servers provide the foundation for enterprise AI, delivering faster training, distributed inference and reduced time to insights - all while offering flexible cooling options to align with diverse enterprise strategies: Dell PowerEdge XE9785 and XE9785L are purpose-built for next-generation AI and HPC workloads. The air-cooled XE97...

Dal Vangelo secondo LucaIn quel tempo, Gesù disse una parabola, perché era vicino a Gerusalemme ed essi pensavano che il regno di Dio dovesse manifestarsi da un momento all'altro.Disse dunque: «Un uomo di nobile famiglia partì per un paese lontano, per ricevere il titolo di re e poi ritornare. Chiamati dieci dei suoi servi, consegnò loro dieci monete d'oro, dicendo: “Fatele fruttare fino al mio ritorno”. Ma i suoi cittadini lo odiavano e mandarono dietro di lui una delegazione a dire: “Non vogliamo che costui venga a regnare su di noi”. Dopo aver ricevuto il titolo di re, egli ritornò e fece chiamare quei servi a cui aveva consegnato il denaro, per sapere quanto ciascuno avesse guadagnato.Si presentò il primo e disse: “Signore, la tua moneta d'oro ne ha fruttate dieci”. Gli disse: “Bene, servo buono! Poiché ti sei mostrato fedele nel poco, ricevi il potere sopra dieci città”.Poi si presentò il secondo e disse: “Signore, la tua moneta d'oro ne ha fruttate cinque”. Anche a questo disse: “Tu pure sarai a capo di cinque città”.Venne poi anche un altro e disse: “Signore, ecco la tua moneta d'oro, che ho tenuto nascosta in un fazzoletto; avevo paura di te, che sei un uomo severo: prendi quello che non hai messo in deposito e mieti quello che non hai seminato”. Gli rispose: “Dalle tue stesse parole ti giudico, servo malvagio! Sapevi che sono un uomo severo, che prendo quello che non ho messo in deposito e mieto quello che non ho seminato: perché allora non hai consegnato il mio denaro a una banca? Al mio ritorno l'avrei riscosso con gli interessi”. Disse poi ai presenti: “Toglietegli la moneta d'oro e datela a colui che ne ha dieci”. Gli risposero: “Signore, ne ha già dieci!”. “Io vi dico: A chi ha, sarà dato; invece a chi non ha, sarà tolto anche quello che ha. E quei miei nemici, che non volevano che io diventassi loro re, conduceteli qui e uccideteli davanti a me”».Dette queste cose, Gesù camminava davanti a tutti salendo verso Gerusalemme.Parola del Signore

Immagina un peluche che insegna a tuo figlio il bondage. Non è un film distopico, è KUMMA, l'orso AI di FoloToy ritirato dal mercato. Dotato di GPT-4o, questo ''compagno di giochi'' è stato scoperto a dare istruzioni su sesso, parafilie e come accendere fiammiferi.È la follia del 'Far West AI': stiamo usando i bambini come beta-tester involontari per tecnologie immature, trasformando la loro crescita in un esperimento. Un cortocircuito totale tra corsa all'oro e assenza di buonsenso.È questo il futuro che vogliamo? Ne parlo in questa puntata.~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Io sono Francesco Cecchetti, consulente paesaggistico e agronomico e aiuto le persone a fiorire insieme al proprio giardino. Stai ascoltando Giardino Rivelato, dal 2019 il podcast per chi crede fermamente che tutte le persone hanno bisogno di un giardino. Quali argomenti ti interessano di più? Preferisci i consigli pratici o le spiegazioni scientifiche?In questo episodio speciale ti chiedo cosa ne pensi, mentre sullo sfondo c'è la Lava Lamp Simulator di Lucia Gomez (https://lucia-gomez.github.io/lava-lamp/). Scrivimi nei commenti cosa vorresti ascoltare!Sostieni e finanzia Giardino Rivelato: https://www.patreon.com/francescocecchetti Vieni a trovarmi su giardinorivelato.it

In quel tempo, Gesù disse una parabola, perché era vicino a Gerusalemme ed essi pensavano che il regno di Dio dovesse manifestarsi da un momento all'altro. Disse dunque: «Un uomo di nobile famiglia partì per un paese lontano, per ricevere il titolo di re e poi ritornare. Chiamati dieci dei suoi servi, consegnò loro dieci monete d'oro, dicendo: "Fatele fruttare fino al mio ritorno". Ma i suoi cittadini lo odiavano e mandarono dietro di lui una delegazione a dire: "Non vogliamo che costui venga a regnare su di noi". Dopo aver ricevuto il titolo di re, egli ritornò e fece chiamare quei servi a cui aveva consegnato il denaro, per sapere quanto ciascuno avesse guadagnato. Si presentò il primo e disse: "Signore, la tua moneta d'oro ne ha fruttate dieci". Gli disse: "Bene, servo buono! Poiché ti sei mostrato fedele nel poco, ricevi il potere sopra dieci città". Poi si presentò il secondo e disse: "Signore, la tua moneta d'oro ne ha fruttate cinque". Anche a questo disse: "Tu pure sarai a capo di cinque città". Venne poi anche un altro e disse: "Signore, ecco la tua moneta d'oro, che ho tenuto nascosta in un fazzoletto; avevo paura di te, che sei un uomo severo: prendi quello che non hai messo in deposito e mieti quello che non hai seminato". Gli rispose: "Dalle tue stesse parole ti giudico, servo malvagio! Sapevi che sono un uomo severo, che prendo quello che non ho messo in deposito e mieto quello che non ho seminato: perché allora non hai consegnato il mio denaro a una banca? Al mio ritorno l'avrei riscosso con gli interessi". Disse poi ai presenti: "Toglietegli la moneta d'oro e datela a colui che ne ha dieci". Gli risposero: "Signore, ne ha già dieci!". "Io vi dico: A chi ha, sarà dato; invece a chi non ha, sarà tolto anche quello che ha. E quei miei nemici, che non volevano che io diventassi loro re, conduceteli qui e uccideteli davanti a me"». Dette queste cose, Gesù camminava davanti a tutti salendo verso Gerusalemme.

In this episode of Improv and Magic, we spotlight the transformative world of improvisation with guest Jill Eickmann, co-founder and Artistic Director of Leela Improv Theatre. Known for her holistic approach to improv, Jill shares insights on ensemble building, truthful artistic play, and the healing power of performance.Jill Eickmann is a nationally recognized improvisational theatre artist, director, and educator. She co-founded Leela Improv, a bi-coastal training center and theatre company based in San Francisco and Raleigh. With over 20 years of experience, Jill has designed Leela's seven-level improv curriculum, rooted in authenticity, collaboration, and joyful play.Her background includes an MA in Drama Therapy from the California Institute of Integral Studies, training with renowned institutions such as iO, Annoyance Theatre, and Upright Citizens Brigade, and corporate workshops for companies like Google, YouTube, Facebook, IBM, Visa, and McKinsey & Company.Beyond teaching, Jill is a performer and drama therapist who integrates improvisation with therapeutic practices, emphasizing connection, creativity, and self-expression.In this episode, Jill discusses the mission of Leela Improv: truthful, artistic play that blends authenticity with ensemble-driven creativity. She explores how improv fosters community, risk-taking, and resilience, both on stage and in everyday life. Jill shares her journey from studying acting and drama therapy to building one of the most respected improv training centers in the U.S.Tune in to hear Jill Eickmann's inspiring perspective on improvisation as both an art form and a tool for personal growth. This episode is a must-listen for anyone passionate about improv, theatre, or creative collaboration.Find out more about Jill at jilleickmann.com, and follow Leela Improv Theater at leela-nc.com.Don't forget to like and review! For more information on LD Madera and how you can sponsor an episode of Improv and Magic, visit ldmadera.com.

Get PUMPED. This week we're joined by charming guest and UK's thickest boy - MC Hammersmith! It's a fully improvised musical, complete with melodious mayors, brutish boys, critical crosswords and more! Get your reps in on this all new Charm Scene! LADS LADS LADS. --- MC Hammersmith (the alias of Will Naameh), is a multi-award winning hip hop comedian.
He is the world's leading rapper to ever emerge from the ghetto of middle class west London. In his live shows, MC Hammersmith performs improvised hip hop comedy. The lyrics and rhymes of his raps are 100% improvised and based entirely on audience suggestions. In this guise he has won numerous comedy awards, headlined weekends at every major comedy club in the UK, sold out multiple consecutive runs at the Edinburgh Fringe Festival, supported Jason Manford on his live arena tour, and is currently on his third nationwide solo tour. He also writes and performs scripted hip hop comedy tracks, which have gone viral on numerous platforms – most notably racking up over 100 million views on TikTok. He has over 1M followers across social media. He has performed alongside famous hip hop and rap artists – most notably rapping for Dave in a viral “Guess The Musician” Beta Squad video, and being invited to freestyle at R.A. The Rugged Man's London live show. He is also a writer for acclaimed YouTube series Epic Rap Battles of History. Having started comedy as an improvisational comedian, he trained at Second City Chicago, iO, Annoyance, and UCB New York. He still performs improv today, in some of the world's biggest touring improv shows – he can frequently be spotted improvising with Baby Wants Candy, Shamilton, and The Spontaneous Players at the Edinburgh Fringe Festival and across the globe. He has headlined numerous international improv festivals, and was the first person in the UK to perform improv in an arena. @mc_hammersmith --- Cast: Lily Ludwig, Austin Packard, MC Hammersmith Music Director: Sam Scheidler Drums: Chris Ditton Follow us @CharmScenePod on Instagram, TikTok, and YouTube, join our Discord, or shoot us a message at CharmScenePod@gmail.com!"

In this episode, we welcome Autumn Durald Arkapaw, ASC. Autumn has shot films including Sinners, The Last Showgirl, Black Panther: Wakanda Forever, Beastie Boys Story, “Loki” and Palo Alto. In our chat, she shares about her roots, early cinematic inspirations, pathway into filmmaking, and how she approached the cinematography of Sinners. Autumn also talks about working with IMAX cameras, her lens choices, and other insights into the making of this standout film of 2025.“The Making Of” is presented by AJA:UDC-4K: More than just an average 12G-SDI and HDMI up/down/cross converterAJA's newest Mini-Converter boasts powerful 12G-SDI and HDMI 2.0 I/O, 4K/UltraHD/2K/HD scaling, frame sync, frame rate conversion, and more. Unlocking an expansive range of conversion possibilities, UDC-4K enables teams to get disparate sources into a common format and timing reference. Explore how UDC-4K solves some of the most common production and post challenges here.Shoot. Store. Secure. Smile.The OWC Guardian is a bus‑powered, portable NVMe SSD featuring 256‑bit AES OPAL hardware encryption and a color touch‑screen for intuitive, secure access. With up to 1,000 MB/s real‑world transfer speeds, platform‑agnostic operation (Mac, PC, iPad Pro), and a rugged anodized aluminum enclosure, it's built to protect audit‑sensitive media and projects anytime, anywhere. Learn more hereMeet Stream Deck Studio:Meet Stream Deck Studio, the ultimate control surface designed for professional broadcast and live production environments. Built on the iconic Elgato hardware and powered by Bitfocus software, it offers a hyper-customizable experience that simplifies even the most complex workflows. With compatibility across hundreds of devices from the industry's top vendors, Stream Deck Studio gives you complete command over your production setup, making it easier than ever to create seamless, high-quality broadcasts. Call Videoguys at 800-323-2325 to learn more and take your production control to the next level today! Explore hereWomen in Media — Holiday Toast 2025Dec 6th | 10am – 2pmHotel Sofitel | Beverly Hills, CAJoin Women In Media as we raise a glass to legendary women of the entertainment industry. There will be a champagne brunch, silent auction, panel with honorees, and celebratory toasts by their toastmasters.Holiday Toast 2025 Honorees include Ashley Nicole Black, Writer/Actor (Shrinking, Ted Lasso, A Black Lady Sketch Show), Toastmaster Chelsea Devantez, Comedian, Writer (The Problem with John Stewart, Girls5Eva), Krystina Figg, Best Boy Grip, Grip (Superman, Killers of the Flower Moon, Dunkirk), and Mandy Walker, AM, ACS, ASC, Director of Photography (Elvis, Hidden Figures, Mulan), President of the American Society of Cinematographers. Get tickets and tables herePodcast Rewind:Nov. 2025 - Ep. 104…Advertise in this newsletter and reach 250K film and TV industry professionals each week. For more information, please email mvalinsky@me.com Get full access to The Making Of at themakingof.substack.com/subscribe

Vorresti ricevere notizie, saluti, auguri dalle Apostole della Vita Interiore?Lasciaci i tuoi contatti cliccando il link qui sotto e con la nostra nuova rubrica digitale potremo raggiungerti.https://www.it.apostlesofil.com/database/- Premi il tasto PLAY per ascoltare la catechesi del giorno e condividi con altri se vuoi -+ Dal Vangelo secondo Luca +In quel tempo, Gesù disse una parabola, perché era vicino a Gerusalemme ed essi pensavano che il regno di Dio dovesse manifestarsi da un momento all'altro.Disse dunque: «Un uomo di nobile famiglia partì per un paese lontano, per ricevere il titolo di re e poi ritornare. Chiamati dieci dei suoi servi, consegnò loro dieci monete d'oro, dicendo: "Fatele fruttare fino al mio ritorno". Ma i suoi cittadini lo odiavano e mandarono dietro di lui una delegazione a dire: "Non vogliamo che costui venga a regnare su di noi". Dopo aver ricevuto il titolo di re, egli ritornò e fece chiamare quei servi a cui aveva consegnato il denaro, per sapere quanto ciascuno avesse guadagnato.Si presentò il primo e disse: "Signore, la tua moneta d'oro ne ha fruttate dieci". Gli disse: "Bene, servo buono! Poiché ti sei mostrato fedele nel poco, ricevi il potere sopra dieci città".Poi si presentò il secondo e disse: "Signore, la tua moneta d'oro ne ha fruttate cinque". Anche a questo disse: "Tu pure sarai a capo di cinque città".Venne poi anche un altro e disse: "Signore, ecco la tua moneta d'oro, che ho tenuto nascosta in un fazzoletto; avevo paura di te, che sei un uomo severo: prendi quello che non hai messo in deposito e mieti quello che non hai seminato". Gli rispose: "Dalle tue stesse parole ti giudico, servo malvagio! Sapevi che sono un uomo severo, che prendo quello che non ho messo in deposito e mieto quello che non ho seminato: perché allora non hai consegnato il mio denaro a una banca? Al mio ritorno l'avrei riscosso con gli interessi". Disse poi ai presenti: "Toglietegli la moneta d'oro e datela a colui che ne ha dieci". Gli risposero: "Signore, ne ha già dieci!". "Io vi dico: A chi ha, sarà dato; invece a chi non ha, sarà tolto anche quello che ha. E quei miei nemici, che non volevano che io diventassi loro re, conduceteli qui e uccideteli davanti a me"».Dette queste cose, Gesù camminava davanti a tutti salendo verso Gerusalemme.Parola del Signore.

Topics covered in this episode: Possibility of a new website for Django aiosqlitepool deptry browsr Extras Joke Watch on YouTube About the show Sponsored by us! Support our work through: Our courses at Talk Python Training The Complete pytest Course Patreon Supporters Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Possibility of a new website for Django Current Django site: djangoproject.com Adam Hill's in progress redesign idea: django-homepage.adamghill.com Commentary in the Want to work on a homepage site redesign? discussion Michael #2: aiosqlitepool

In episode 109, we sit down with Drs. Ian Katz and Shelly Rauvola, co-editors of a groundbreaking special issue in Industrial and Organizational Psychology. Together, we explore how current public policy changes in the United States are reshaping the world of work, from employee well-being and marginalized worker experiences to the future of I-O psychology education and research.Key takeaways include:* How policy changes impact HR practices, training, and organizational functioning* The chilling effect of political climates on academic freedom and research* Why behavioral scientists must engage in policy conversations* How I-O psychology can respond using existing theories and evidence-based practices* A call to action for researchers and practitioners to advocate for worker dignity and evidence-based decision-makingThis episode is essential listening for anyone invested in the future of work, science advocacy, and the role of IO psychology in shaping policy.Find the special issue here: https://www.cambridge.org/core/journals/industrial-and-organizational-psychology/issue/380836BA2B93123CE626AACDCB5DF7DAFind Ian Katz here: https://csh.depaul.edu/faculty-staff/faculty-a-z/Pages/psychology/ian-katz.aspxFind Shelly Rauvola here: https://csh.depaul.edu/faculty-staff/faculty-a-z/Pages/psychology/shelly-rauvola.aspx This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit healthywork.substack.com

durée : 00:10:04 - Les Midis de Culture - par : Marie Labory - Dans "Barbara (par Barbara)" présenté au Théâtre du Rond Point, la comédienne Marie-Sophie Ferdane redonne vie aux mots de la chanteuse à travers un montage d'interviews et d'écrits inédits. Aux côtés du musicien Olivier Marguerit, elle esquisse un portrait sensible et vibrant de l'artiste. - réalisation : Laurence Malonda - invités : Victor Inisan docteur en études théâtrales, dramaturge et critique ; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

durée : 00:17:40 - Les Midis de Culture - par : Marie Labory - Avec "Musée Duras", Julien Gosselin et seize jeunes interprètes du CNSAD explorent onze textes de Marguerite Duras réunis dans un musée imaginaire. Loin d'une rétrospective figée, le spectacle propose un face-à-face vivant, à découvrir sur dix heures ou par fragments aux Ateliers Berthier Paris 17 - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Victor Inisan docteur en études théâtrales, dramaturge et critique 

durée : 00:27:42 - Les Midis de Culture - par : Marie Labory - Au programme de notre débat critique aujourd'hui, pour bien commencer la semaine, du théâtre avec "Musée Duras" deJulien Gosselin et "Barbara (par Barbara)" de Clémentine Deroudille, Arnaud Cathrine, Emmanuel Noblet - réalisation : Laurence Malonda - invités : Victor Inisan docteur en études théâtrales, dramaturge et critique ; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

A Gorizia, qualche mese fa, abbiamo realizzato una magnifica presentazione a due con Guido Damini, ottimo e simpaticissimo divulgatore. Io e Guido siamo d'accordo che non si dovrebbe replicare o registrare un evento dal vivo, ma in questo caso abbiamo fatto un'eccezione, perché potevamo finalmente mostrare le slides (che non c'erano a Gorizia per motivi...tecnici) Se volete apprezzare di più l'episodio, vi conviene vederlo su Spotify come videopodcast, perché vedrete anche le slides. --- Podcast di Guido Le caporetto degli altri Cenni storici per fare lo splendido --- Tutti i link di "Storia d'Italia": sito, libri, guerre incivili, patreon, tipeee... ⁠⁠⁠https://linktr.ee/italiastoria⁠⁠⁠ --- Per comprare "Quando Venezia distrusse l'Impero romano": Amazon libro: ⁠⁠⁠https://amzn.to/4gR4tzG⁠⁠⁠ Amazon ebook: ⁠⁠⁠https://amzn.to/4hWFn36⁠⁠⁠ Altre opere letterarie: Per comprare "Ammiano": ⁠⁠⁠acquista fumetto⁠⁠⁠ Per comprare "Per un pugno di barbari":⁠⁠⁠https://amzn.to/3rniBwd⁠⁠⁠ Per comprare "Il miglior nemico di Roma": ⁠⁠⁠https://amzn.to/3Zgzy8w⁠⁠⁠ --- Per supportarmi: ⁠⁠⁠www.patreon.com/italiastoria⁠⁠⁠ ⁠⁠⁠https://it.tipeee.com/italiastoria⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

A second bite of episode 257: You have the degree now, what? Revisiting the conversation surrounding the transition from study to practice and the realities of trying to find an I/O specific role. We explored what it really takes to land meaningful roles, navigate the uncertainty, and build confidence when the “real world” doesn't match the textbook.

Beth GMs for Ellie, Crash, and Io. This episode: The Logistics Trio stop by the local glass factory to pick up some bread crumbs and sticky notes. Follow this series on… ▶ RSS: https://aaronbsmith.com/cogwheel/tag/gurpswars/podcast ▶ Patreon: https://www.patreon.com/cogwheelgaming ▶ Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art chirp.enworld.org tabletop.vip MP3 Download: GURPS Wars … Continue reading "GURPS Wars S1 Ep 83: Factory Tour"

IAD Talks - týždenné spravodajstvo. Japonské akcie zaznamenali v októbri najvýraznejší mesačný rast od začiatku 90. rokov. Index Nikkei 225 posilnil o 16,6 % a TOPIX vystúpil na nové historické maximá, čím sa Japonsko zaradilo medzi najvýkonnejšie trhy roka. Viac o tejto téme si môžete vypočuť v našom pravidelnom komentári z finančných trhov...IAD TALKS, týždenník, IAD Investments, správ. spol., a.s., Malý trh 2/A, 811 08 Bratislava, IČO: 17 330 254, dátum vydania: 17.11.2025, 53/2025, EV 139/23/EPP..*UPOZORNENIE. Tento materiál je marketingovým oznámením. Kompletné znenie upozornenia nájdete na stránke www.iad.sk/marketingoveoznamenia

Nel 2024 in Italia oltre 1 MILIONE di contratti luce/gas (fino a 1 miliardo €) e 800.000 telefonia mobile sono chiusi via CALL CENTER, anche se sei nel registro opposizioni.Dal 19 novembre 2025 scatteranno i veri blocchi anti-spoofing, ma i truffatori sfruttano numeri cellulari falsi finché possono: ogni nuova norma viene aggirata subito. Sanzioni GIGANTI (Enel: 79 milioni €), ma ai big conviene rischiare. Unica soluzione reale? Vietare i contratti telefonici, come sta facendo la Spagna.Un mini documentario per capirne di più su call center, registro delle opposizioni, giro d'affari, spoofing e tanto tanto altro...~~~~~ INGAGGI E SPONSORSHIP ~~~~~ Per contatti commerciali: sales@matteoflora.comPer consulenze legali: info@42LawFirm.it~~~~~ SOSTIENI IL CANALE! ~~~~~Con la Membership PRO puoi supportare il Canale » https://link.mgpf.it/proSe vuoi qui la mia attrezzatura » https://mgpf.it/attrezzatura~~~~~ SEGUIMI ANCHE ONLINE CON LE NOTIFICHE! ~~~~~» CANALE WHATSAPP » https://link.mgpf.it/wa» CANALE TELEGRAM » https://mgpf.it/tg» CORSO (Gratis) IN FUTURO » https://mgpf.it/nl» NEWSLETTER » https://mgpf.it/nl~~~~~ CIAO INTERNET E MATTEO FLORA ~~~~~ Questo è “Ciao Internet!” la prima e più seguita trasmissione di TECH POLICY in lingua italiana, online su YouTube e in Podcast.Io sono MATTEO FLORA e sono:» Professore in Fondamenti di Sicurezza delle AI e delle SuperIntelligenze (ESE)» Professore ac in Corporate Reputation e Crisis Management (Pavia).Sono un Imprenditore Seriale del digitale e ho fondato:» The Fool » https://thefool.it - La società italiana leader di Customer Insight» The Magician » https://themagician.agency - Atelier di Advocacy e Gestione della Crisi» 42 Law Firm » https://42lf.it - Lo Studio Legale per la Trasformazione Digitale » ...e tante altre qui: https://matteoflora.com/#aziendeSono Future Leader (IVLP) del Dipartimento di Stato USA sotto Amministrazione Obama nel programma “Combating Cybercrime (2012)”.Sono Presidente di PermessoNegato, l'associazione italiana che si occupa di Pornografia Non- Consensuale e Revenge Porn.Conduco in TV “Intelligenze Artificiali” su Mediaset/TgCom.

Ciao ciccini e ciccine, pronti per un mese intero di fuoco brasiliano che vi farà sudare più di un churrasco dimenticato sulla griglia? Io e Marianna siamo atterrati a Fortaleza, abbiamo noleggiato un UTV e ci siamo lanciati sulle dune di Jericoacoara come due pazzi in fuga dal fisco! Sabbia in bocca, vento nei capelli e tramonti che sembrano filtri Instagram ma sono veri. Poi Salvador: capoeira che ti spacca il culo (in senso buono), samba fino all'alba e quella magia nera che ti guarda negli occhi e ti dice “tranquillo, è solo candomblé… o forse no”. Un viaggio che puzza di caipirinha, mare e guai belli.

[Swedish: Three hundred and ninety-three – Dressed up] We're looking good thanks to these banging tracks in languages that aren't English. You will too. Michael and Io explore Icelandic raves,... LEARN MORE The post Trehundra nittiotre – Klädd up till tänderna appeared first on babble POP!.

In this episode, we welcome Vincent Piazza. Vincent stars in “Tulsa King,” and is also known for his lead role as Lucky Luciano in “Boardwalk Empire.” In our chat, we hear about his NYC roots, education, career path, and approach to his character in “Tulsa King.” In addition, Vincent offers insights and recommendations for actors and emerging filmmakers today.“The Making Of” is presented by AJA:UDC-4K: More than just an average 12G-SDI and HDMI up/down/cross converterAJA's newest Mini-Converter boasts powerful 12G-SDI and HDMI 2.0 I/O, 4K/UltraHD/2K/HD scaling, frame sync, frame rate conversion, and more. Unlocking an expansive range of conversion possibilities, UDC-4K enables teams to get disparate sources into a common format and timing reference. Explore how UDC-4K solves some of the most common production and post challenges.Shoot. Store. Secure. Smile.The OWC Guardian is a bus‑powered, portable NVMe SSD featuring 256‑bit AES OPAL hardware encryption and a color touch‑screen for intuitive, secure access. With up to 1,000 MB/s real‑world transfer speeds, platform‑agnostic operation (Mac, PC, iPad Pro), and a rugged anodized aluminum enclosure, it's built to protect audit‑sensitive media and projects anytime, anywhere. Learn more hereZEISS Events at CamerimageImmersive Action Cinematography with Movement Specialist Daniel IlabacaTuesday, November 1814:30 - 16:00Venue: CKK Jordanki – Seminar Room and Camerimage Online PlatformFormer stuntman and Parkour performer turned filmmaker Daniel Ilabaca has been researching immersive filming for a while. Now with smaller camera bodies and compact full format lenses such as the ZEISS Nano Primes, it's becoming possible to literally wear the camera without compromising the quality of the footage. Be a fly on the wall as Daniel turns the seminar room into a production office: from screenwriting to shot-listing, location scouting, and camera rigging, he'll take us on a gliding tour of his creative process, as he goes through the preproduction of his upcoming passion project. Learn more hereMeet Stream Deck Studio:Meet Stream Deck Studio, the ultimate control surface designed for professional broadcast and live production environments. Built on the iconic Elgato hardware and powered by Bitfocus software, it offers a hyper-customizable experience that simplifies even the most complex workflows. With compatibility across hundreds of devices from the industry's top vendors, Stream Deck Studio gives you complete command over your production setup, making it easier than ever to create seamless, high-quality broadcasts. Call Videoguys at 800-323-2325 to learn more and take your production control to the next level today! Explore herePodcast Rewind:Nov. 2025 - Ep. 103…Advertise in “The Making Of” and reach 250K film & TV industry pros each week. For more information, email mvalinsky@me.com Get full access to The Making Of at themakingof.substack.com/subscribe

Vorresti ricevere notizie, saluti, auguri dalle Apostole della Vita Interiore?Lasciaci i tuoi contatti cliccando il link qui sotto e con la nostra nuova rubrica digitale potremo raggiungerti.https://www.it.apostlesofil.com/database/- Premi il tasto PLAY per ascoltare la catechesi del giorno e condividi con altri se vuoi -+ Dal Vangelo secondo Luca +In quel tempo, Gesù diceva ai suoi discepoli una parabola sulla necessità di pregare sempre, senza stancarsi mai:«In una città viveva un giudice, che non temeva Dio né aveva riguardo per alcuno. In quella città c'era anche una vedova, che andava da lui e gli diceva: "Fammi giustizia contro il mio avversario".Per un po' di tempo egli non volle; ma poi disse tra sé: "Anche se non temo Dio e non ho riguardo per alcuno, dato che questa vedova mi dà tanto fastidio, le farò giustizia perché non venga continuamente a importunarmi"».E il Signore soggiunse: «Ascoltate ciò che dice il giudice disonesto. E Dio non farà forse giustizia ai suoi eletti, che gridano giorno e notte verso di lui? Li farà forse aspettare a lungo? Io vi dico che farà loro giustizia prontamente. Ma il Figlio dell'uomo, quando verrà, troverà la fede sulla terra?».Parola del Signore.

durée : 00:12:34 - Les Midis de Culture - par : Marie Labory - Inspirée du roman iconique de Gaston Leroux, écrit en 1910, cette toute nouvelle adaptation du "Fantôme de l'Opéra" prend la forme d'une comédie musicale. Présentée au Théâtre Antoine, l'histoire reprend les personnages emblématiques dans une lecture contemporaine de l'œuvre. - réalisation : Laurence Malonda - invités : Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Zoé Sfez Productrice de La Série musicale sur France Culture; Carole Boinet Journaliste française

durée : 00:25:47 - Les Midis de Culture - par : Marie Labory - Aujourd'hui, au menu de notre débat critique, pour bien terminer la semaine, des comédies musicales avec "La petite boutique des horreurs" & "Le fantôme de l'Opéra" et le coup de coeur de Carole Boinet pour "Loose Fist" de Arhant Shrestha - réalisation : Laurence Malonda - invités : Zoé Sfez Productrice de La Série musicale sur France Culture; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O; Carole Boinet Journaliste française

durée : 00:12:29 - Les Midis de Culture - par : Marie Labory - Né Off-Broadway en 1982, la comédie musicale "La Petite Boutique des Horreurs" revient au Théâtre de la Porte Saint-Martin. Seymour, jeune fleuriste, découvre un jour une plante, miraculeuse, mais carnivore... Humour noir et surprises scéniques font revivre l'esprit déjante du musical culte. - réalisation : Laurence Malonda - invités : Zoé Sfez Productrice de La Série musicale sur France Culture; Marie Sorbier Productrice du "Point Culture" sur France Culture, et rédactrice en chef de I/O

In today's episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with genitourinary (GU) cancer expert Scott T. Tagawa, MD, MS, FACP, FASCO, about the rapidly evolving treatment paradigms for prostate and kidney cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Tagawa is a professor of medicine and urology at Weill Cornell Medicine, as well as an attending physician at NewYork-Presbyterian – Weill Cornell Medical Center in New York, New York. Their conversation began with a focus on prostate-specific membrane antigen (PSMA)–positive prostate cancer. Dr Tagawa explained that PSMA is a cell surface protein, and that PSMA imaging agents are commonly used to assess biochemical recurrence and perform initial disease staging. He noted that therapy-related adverse effects are often site-specific, including dry mouth/change in taste, and myelosuppression from the radiation payload. For monitoring long-term safety, Dr Tagawa emphasized that renal function must be tracked. Beyond PSMA, other prostate cancer targets include TROP-2, B7-H3, and markers specific to aggressive or neuroendocrine variants, such as DLL3, he reported. In advanced GU cancers, circulating tumor DNA (ctDNA) testing is increasingly important, Dr Tagawa highlighted. In prostate cancer, ctDNA testing is used to assess homologous recombination deficiency (HRD) status and BRCA expression, he said, explaining that evidence for the use of ctDNA testing in GU cancers stems from findings with this type of assay to evaluate minimal residual disease levels in urothelial cancer. He noted that studies show that if patients with urothelial cancer become ctDNA positive within the first year of receiving neoadjuvant chemotherapy, they benefit from treatment with atezolizumab (Tecentriq). Similarly, he stated that patients with previously untreated HRD-positive metastatic prostate cancer also see a progression-free survival benefit when a PARP inhibitor is added to an androgen deprivation therapy/androgen receptor pathway inhibitor backbone. Shifting the conversation to the management of frontline advanced clear cell renal cell carcinoma (RCC), the experts reviewed standard approaches, which involve an immune-oncology (IO) agent plus either a CTLA-4 inhibitor or a VEGF TKI. Tagawa noted that IO/VEGF TKI combinations may be preferred for symptomatic patients needing a rapid response, whereas IO/IO combinations may offer greater potential for treatment cessation. He brought up a key distinction in RCC, which is that re-instituting PD-1/PD-L1 inhibition upon progression in the metastatic setting has generally shown no benefit. Dr Levy brought a broad scope to the GU cancer discussion through his lung cancer expertise, introducing parallels between the treatment paradigms. The interview provided an opportunity to show the importance of creating connections across oncology specialties to bring nuanced perspectives to future advances in clinical research and patient care.

In questo articolo affrontiamo uno degli argomenti che più vi fa venire il mal di testa: quando usare l'ausiliare ESSERE e quando usare AVERE? Lo so, lo so... ogni volta che dovete formare un tempo composto vi viene il panico! "Ma si dice ho andato o sono andato?" "È ho piaciuto o sono piaciuto?" Tranquilli! Vi spiego tutto con regole chiarissime e trucchi infallibili. E alla fine di questo articolo, non avrete più dubbi! Promesso! Tempi Composti: Come scegliere l'ausiliare giusto? Quando Usare "ESSERE"? L'ausiliare ESSERE si utilizza in diversi casi specifici che è importante conoscere e riconoscere. La caratteristica principale dei verbi che richiedono "essere" è che il participio passato deve concordare in genere e numero con il soggetto. 1) Verbi di Movimento (Spostamento da un Luogo all'Altro) I verbi di movimento che indicano uno spostamento da un posto all'altro o un cambiamento di posizione richiedono sempre l'ausiliare ESSERE. Questi verbi esprimono l'azione di muoversi, spostarsi o cambiare la propria collocazione nello spazio. Verbi principali: andare, venire, tornare, partire, uscire, entrare, cadere, fuggire, arrivare, salire, scendere, rientrare RICORDA: Con l'ausiliare "essere", devi concordare il participio passato in genere e numero con il soggetto. Esempi pratici: Io sono andata al supermercato (soggetto femminile singolare) Paolo è tornato dal suo viaggio ieri (soggetto maschile singolare) Noi siamo partiti per Parigi un anno fa (soggetto maschile plurale o misto) Le tue sorelle sono venute a casa mia ieri (soggetto femminile plurale) Maria e Luca sono usciti insieme stasera (gruppo misto: si usa il maschile plurale) Il treno è arrivato in ritardo stamattina Sono salita al terzo piano a piedi ATTENZIONE: Eccezioni con "AVERE" Alcuni verbi che indicano movimento, ma senza specificare la destinazione o il punto di arrivo, utilizzano invece l'ausiliare AVERE: Verbi con AVERE: ballare, camminare, nuotare, correre, viaggiare, passeggiare Perché usano AVERE? Perché questi verbi descrivono un'azione continuativa senza indicare uno spostamento specifico da un punto A a un punto B. Esempi: Ho camminato per due ore (movimento generico, nessuna destinazione specifica) Abbiamo ballato tutta la notte Ho nuotato in piscina Hanno corso per mantenersi in forma NOTA BENE: Anche CADERE richiede sempre l'ausiliare "essere" perché indica un cambiamento di posizione: Sono caduto dalle scale. 2) Verbi di Permanenza (Stare in un Luogo o in una Condizione) I verbi di permanenza indicano il fatto di rimanere in un certo luogo o di mantenere una determinata condizione per un periodo di tempo. Esprimono staticità piuttosto che movimento. Verbi principali: stare, restare, rimanere, durare Esempi pratici: Ieri sono rimasta a casa tutto il giorno perché dovevo lavorare (permanenza in un luogo) Luca è stato fermo tutto il tempo perché aveva paura (permanenza in una condizione) Loro sono rimasti dentro perché stava diluviando Il film è durato troppo (durata temporale) Siamo stati in silenzio per rispetto Le ragazze sono rimaste sole tutto il weekend Questi verbi esprimono la continuità di uno stato o di una posizione, senza implicare movimento o cambiamento attivo. 3) Verbi che Esprimono Cambiamenti di Stato Questa categoria include tutti i verbi che indicano una trasformazione, un cambiamento fisico o psicologico, o l'inizio/fine di uno stato. Sono verbi che descrivono come qualcosa o qualcuno diventa diverso da come era prima. Verbi principali: nascere, morire, crescere, diventare, invecchiare, dimagrire, ingrassare, impazzire, arrossire, guarire, ammalarsi, migliorare, peggiorare, cambiare, scomparire, apparire Esempi pratici con spiegazione: Sono nata nel 1996 (inizio dell'esistenza) Luca è diventato famoso grazie a quel video (cambiamento di condizione sociale)

Vorresti ricevere notizie, saluti, auguri dalle Apostole della Vita Interiore?Lasciaci i tuoi contatti cliccando il link qui sotto e con la nostra nuova rubrica digitale potremo raggiungerti.https://www.it.apostlesofil.com/database/- Premi il tasto PLAY per ascoltare la catechesi del giorno e condividi con altri se vuoi -+ Dal Vangelo secondo Luca +In quel tempo, Gesù disse ai suoi discepoli:«Come avvenne nei giorni di Noè, così sarà nei giorni del Figlio dell'uomo: mangiavano, bevevano, prendevano moglie, prendevano marito, fino al giorno in cui Noè entrò nell'arca e venne il diluvio e li fece morire tutti.Come avvenne anche nei giorni di Lot: mangiavano, bevevano, compravano, vendevano, piantavano, costruivano; ma, nel giorno in cui Lot uscì da Sòdoma, piovve fuoco e zolfo dal cielo e li fece morire tutti. Così accadrà nel giorno in cui il Figlio dell'uomo si manifesterà.In quel giorno, chi si troverà sulla terrazza e avrà lasciato le sue cose in casa, non scenda a prenderle; così, chi si troverà nel campo, non torni indietro. Ricordatevi della moglie di Lot.Chi cercherà di salvare la propria vita, la perderà; ma chi la perderà, la manterrà viva.Io vi dico: in quella notte, due si troveranno nello stesso letto: l'uno verrà portato via e l'altro lasciato; due donne staranno a macinare nello stesso luogo: l'una verrà portata via e l'altra lasciata».Allora gli chiesero: «Dove, Signore?». Ed egli disse loro: «Dove sarà il cadavere, lì si raduneranno insieme anche gli avvoltoi».Parola del Signore.

In this episode of The Founder's Sandbox, host Brenda McCabe sits down with Chris Daden, CTO of Criteria Corp, to explore what it takes to scale purpose-driven businesses in the era of Work 4.0. Chris shares his fascinating origin story—starting with a childhood shaped by tech-savvy parents and leading to multiple exits, international teams, and leadership at a global talent success platform. He breaks down how Criteria uses science and AI to remove bias from hiring, why soft skills matter more than ever, and how to future-proof your workforce in an AI-augmented world. Learn about his nonprofit, SoCal Tech Forum, and why building trust is essential for AI adoption at scale. transcript: 00:18 Welcome back to the Founder's Sandbox. The Founder's Sandbox is in its fourth season. I'm here, your host, Brenda McCabe, and I'm live this month's podcast is 00:31 from the Founders Space in Pasadena. And I'm joined with my guest, Chris Daden of Criteria Corp. um And a colleague of mine in the startup ecosystem. Welcome, Chris. Thanks for having me. I'm really excited to be here. So am I. So um I want to briefly give some background on the Founder Sandbox for those that are listening in today. um 00:56 Each episode features in-depth conversations with founders of small and mid-sized owner-operated companies and operators that support the ecosystem. And together, through storytelling, we explore how to build scalable, resilient, purpose-driven businesses with great corporate governance. And you're going to discover today with Chris, his origin story. I always like to start with how the person 01:24 that's a guest to my podcast, really started getting involved with the ecosystem of startups. And your story is quite fascinating. I'm gonna give a spoiler alert here. You and I met, I guess two years ago, at a Thai con event where you were on a panel. I was the MC em and we got to talking over dinner and just your origin story and the multiple exits you've had. 01:53 really um lit up a bulb in my mind. said, Chris, you have to be in my podcast. So it's two years later, and I'm so glad that we're making this happen. Lucky to be here. Thank you. forward to it. So this podcast, again, we're going to talk about a lot of things because Chris, not only are the CTO of Criteria Corp, a talent success company, where you help organizations meet objective evidence-based 02:23 talent decisions that both reduce the bias and drive better outcomes. But also, you're a two times 40 under 40. You've had multiple exits of prior companies. You're a speaker, a founder, a board member, and recently you started your own nonprofit in SoCal called the SoCal Tech Forum. 02:51 Oh, and I forgot you're a member of the Forbes Technology Council. we're going to have... Couldn't have said it better. Thank you, Brenda. So with that, again, my episodes on particularly Spotify, we have a title that's on each episode and we've chosen Scaling Work 4.0 for this month's podcast. Again, it's Chris Daden, CTO of Criteria. So let's start. What would you... 03:21 Call your tagline. Tell us about your origin here in Southern California. Sounds great. Well, just a little bit about myself personally. I've been in tech for ah quite a while now. It's really the only career I've ever had working in tech. So I started in my youth, frankly. My father was a member of the British Merchant Navy. you can imagine with that career involved, he traveled all around the world. uh 03:50 Also, of course, gave me lot of inspiration for the global companies that I run today and the teams that I've started around the world. So although my father wasn't directly in computer science, you know, that career of being in the merchant Navy definitely shaped my global perspective. when he stopped working in the merchant ship Navy as an officer, he started developing his own software for weather routing for large 04:21 merchant ships and container ships. So what was amazing about that was it was ran out of a spare bedroom in my parents' house just upstairs while I was growing up there. And uh we used to even have a rack of kind of four by four Dell just desktop computers that were stacked on top of each other with a switch to switch between them. And we're running the workload that my dad made with the software there on those computers. 04:51 It was very visible and evident in my childhood. My first kind of internship was maybe when I was 13 or so ah in the closet of that office. We pulled the doors off and put a desk in it and that was like my internship desk for the summer. started with programming in the dotnet ecosystem. So what year is that more or less? Yeah, it's probably like 2005, 2006. uh 05:21 So it uh was a great introductory language. Fun fact, there's a YouTube video online of me when I'm about that age doing a tutorial of how to make a calculator. So very few people have found that. I'll leave it to the public to find. But you can hear my very young 12-year-old voice in a YouTube video. it's still there. So anyway, that's part of my origin story for sure. That's what got me into computer science. 05:48 My first company, started my senior year of high school. I was aqua hired into an organization in Irvine. And then I got to join what I would call kind of a real company at that time. um One that had, you know, engineers around the globe working on solving problems and SAS for organizations of all kinds. So that's kind of where I kick started my career. I'm spending the next maybe eight to 10 years in Orange County building companies and 06:16 Now I find myself as the CTO of Criteria, which of course I'm not a founder of, but the energy that I like to bring to the team and the passion I have for what the next era of work has to offer gives me that founder-like energy. Yes. So um how long have you been with Criteria? Were you the first CTO? Were you an aqua hire? Tell us a little bit about that. Yeah, great question. So Criteria has a great history, almost 20 years of science and 06:46 um just developing a great core platform that's been used by thousands of customers around the world. I've been there as CTO for the last three and a half years. So when I joined, was right after acquisition of a couple companies in Australia that were great additions to our product portfolio. And one of my roles right away after joining was to help integrate those teams, finish retiring some of the technical debt that comes with acquisitions. um 07:15 really just all the excitement around building for the next chapter of criteria and making sure that I can contribute in my many ways to our success. So back to that tagline that due to your father's um origins in the Navy, m you have a wide global perspective. Tell me about those teams that you had in India before Criteria. 07:41 Yeah, look, I started doing business in India a little over 10 years ago. I was just reflecting on that last week. I had the luxury of visiting my team again. We also just created a new team for criteria. So I was able to go visit them. We all got together for the first time. It was a lot of fun. But about 10 years ago, I started in a city named Indore and that's in the state Madhya Pradesh. And when I started, it was a tier three city. And, you know, I really stumbled across 08:09 who is now my general manager for my last company. I stumbled across meeting him through like a development agency and we really hit it off and you know at the time I was 18 years old and you know was willing to take some risk I guess because I wanted to work with an engineer and had to build my product and company and you know what it's like being a scrappy founder and I just rolled the dice and said sure like 08:34 Why don't you come work for me full time? Let's find your friends as well and let's start a company together. And his name is Vikram. And to this day, he's still the general manager of my last company in automotive SaaS that I had recently exited in like 2021 timeframe. He's still operating that team. Company's going great. So that's been a lot of fun to see that success. But yeah, over a period of 10 years, it's become... 09:00 from a tier three to a tier two city. So things like basic infrastructure have been developed. So just so much fun and so much reflection there. I'm lucky to have, know, that's my, Criteria's new team is now my fourth India venture. So this is my fourth generation. Oh my goodness. It's a scaling work 4.0. So let's go back to Criteria. again, over dinner a couple years ago, 09:29 You started talking about how the science of finding talent is really the bedrock of criteria. And you've been there three and a half years. Talk to us about that, the talent and the science that is driving this company's technology and being used today in hiring across the world. Yeah, I think. 09:58 Hiring is one of those things that we don't always teach hiring managers or people in organizations. I think we were laughing about that. If you're, say, a great senior software engineer and you've been coding for 15 years or something, I think it's assumed that when you get promoted into, say, an engineering manager role, you're now going to be a great hiring manager. And I think hiring science is something that is often... 10:22 underappreciated in organizations, particularly startups and mid-market companies who may not have the resources, right? Because to be good at hiring science, you also have to invest resources in it, right? So really you don't see most really advanced hiring science or like, you know, psychology teams being involved in hiring until the enterprise level. for criteria, we're all about using technology to harness as many what we call talent signals as possible. So we have a 10:52 an assortment of assessment tests that can measure things like your cognitive ability, your adaptiveness, your personality fit to a job role. And we do that in rigorous and scientific ways. I think there are probably more ways to do hiring wrong than to do it correctly. And we take a lot of pride in making sure that our products are always designed to measure those talent signals and even compound them. So as you find 11:19 multiple talent signals across the life cycle of that pre-employment hiring engagement, you get a compounding, really almost like a talent blueprint of the person you're looking to hire, or maybe even like the candidate DNA of that person. And it gives you a depth of information and data about the likelihood they are to succeed for that specific job role you're hiring. And that's really, really valuable to us. And we can talk a bit about why 11:46 that matters more as we enter into this new era of work. Before we go there though, I'm fascinated. What types of talent can Criteria be used for in the hiring process? Is it across all verticals? mean, tell me a bit about that. Criteria is a pretty diverse company. So with 4,000 customers around the world, we are really present in maybe 20 different verticals. So that makes us pretty... 12:15 pretty broad in who can use us for hiring. So, you know, we joke around anything from, you know, hiring for truck drivers all the way to rocket scientists. Like there's customers across the whole spectrum in engineering, venture capital, uh you know, executive management, truck drivers for uh companies, uh frontline workers, all the way up to rocket scientists at companies. 12:45 So recently you were a keynote speaker in London and you provided your closing thoughts on AI in the workforce. So I'm going to steal your thunder right now because you gave this to me and set it up. So work 4.0 belongs to those who pair adaptive mindsets with distinctively, yeah, human skills. Workplace. 13:14 AI will be our most tireless colleague, but the future's real competitive edge is still human potential, continuously renewed. Wow, unpack that for my listeners. Because we're all getting a bit nervous about will we have job security, what do we need to do to retool, and is everybody suitable? Yeah, I think what's kind of amazing is 13:44 um You look at some reports from the World Economic Forum or other entities and they're saying things like by 2030, 39 % of skills related to kind of the current candidate applying in the workforce will be obsolete. Wow, that's a lot. That's a lot. It's almost half, right? And what's amazing about that is then what are we hiring for, right? Because the last few decades of us 14:12 hiring has been so focused on how many years of experience did you have, what degrees do you hold. And it doesn't mean for many people who, right, college is the best fit, getting a degree is the best fit for many people. But ah I think what it highlights is there's more to being workforce ready than only getting these static credentials. And for people like me, I've dropped out of college twice. Both times I had some... 14:41 transactional event with one of my businesses. And that was obviously the right choice for me, right? And I've reflected on that and I feel good about where I'm at and where I came from. But I think workforce readiness these days is going to continue to index on the more dynamic talent signals and the more dynamic credentials we have as opposed to static credentials. So what that means is my ability to think on my feet, critical thinking, adaptive reasoning. 15:11 Those are all things that we kind of measure, if at all, we measure them kind of secondarily in our current process. And these other core talents like digital fluency, AI literacy, self leadership, resilience, those are all things that are more of these dynamic credentials that we need to make sure we measure really, really well, because the reality is with the advent of AI in the work 15:40 place, hard skills are more immediately attainable. And what I mean by that is maybe if I'm hiring for an accountant role, I care more about is that accountant a strategic thinker? Do they understand the tax code to the right depth? Do they understand the strategy for valuation of the business? And then of course they have to click some buttons in QuickBooks or NetSuite or other systems. But I think AI is going to... 16:09 augment the hard skills of our workforce. And that's going to make us more index on the softer skills, emotional intelligence, the adaptability, right? Those dynamic credentials as opposed to how many years have you been clicking buttons in QuickBooks? And it will require, I guess, more critical thinking, right? True. Right? Because you will be your... uh 16:36 day-to-day job will be augmented by AI, leaving you time to upskill or to make those critical decisions, more, I don't know, avenues of strategic development in the company. that's right. Yeah, redeploy to higher value opportunities for sure. think if 30 to 40 % of your day is... 17:04 tasks that can be augmented with AI, then that 30 to 40 % of your human first excellence can be redeployed to other parts of the business. an example is at Criteria, we serve uh tens of millions of assessments, um about 10 to 12 million per year. And we have about five or six million candidates that come through that process. 17:31 when they need technical support or help with the software, they often reach out to our live chatbot. we at Criteria um want to make sure we prioritize a five-star candidate experience. So even though candidates aren't the ones paying for the service, our customers are, we know that our customer satisfaction is tightly linked to how satisfied our candidates are. Got it. uh 17:54 One of the things we had was thousands and thousands of tickets every month from those five million plus candidates coming into our support system. And what we were able to do was augment our support staff with uh AI chat bots that are trained on deep knowledge bases of criteria and past candidate issues and technical troubleshooting. we were able to achieve about a 94 % candidate ticket deflection, which is really, really massive. And it didn't mean that we 18:24 know, laid off half of our support team or something, it means that, you know, those support team members moved into other high value roles in the organization or were able to now redirect their energy to making long lasting materials like help docs and guides that can then further retrain the AI to make that even better. So that's just an example of augmentation of skill and then redeploying that human excellence to another part of the business to help you grow. So it has criteria use the same time. 18:54 methodology for their staff? For our staff, every single person at Criteria goes through our assessment products, of course. We drink our own champagne. I had to ask that question. I'm a little biased, but I think I didn't know about the category before joining Criteria. And again, with my origin story, I've hired hundreds of people around the world. And I will never run another team without using 19:22 a criteria talent success platform to hire those people. So I'm a firm believer and because I didn't know about it before and now I'm using it, it's a big gap in my knowledge. So I would say most of our market potential for criteria doesn't actually know that these tools exist. A lot of them have a retention challenge or they're having an issue hiring the right people and people like me before I joined criteria don't actually know that this tool set is available. part of my mission is to... 19:51 make sure that startups and founders and mid-market companies are aware that this is available because it solves a big problem for us building the best teams. so uh last plug for Criterion, then we're going to move on in the interview here. uh How do um customers experience Criterion? How do they uh get onboarded? mean, what is it, the HR department? Where does, where's the origin? Yeah, really great. So 20:19 We call ourselves a talent success platform because we help people pre-hire with our assessments and video interviewing products. And that's normally the HR talent acquisition leader. So someone who's in charge of recruitment for a company or essentially all the pre-employment functions. And then because we have this rich data set that comes from those pre-employment activities, we have a post-hire product that we call Develop by Criteria. And Develop is designed to use all of that psychometric data 20:48 weekly check-ins with your employees, uh frameworks for behavior to help grow those team members after they're hired using all of that data and science. So a lot of our customers experience criteria on the pre-employment side and then continue to follow through on the post-employment side with our develop product. Wow. Is there patent protection with all of the science that you have developed over the years? I think there's obviously copyright. 21:17 um of our assessment tests. think patents and software are inherently tricky, but we feel really good about the protection of our IP. Excellent, excellent. So let's switch gears. um I met you at the TICON. um You haven't been our keynote speaker yet, but you have moderated panels, and I've seen you in other events. Tell us about what do you enjoy, what do you like to talk about when you're keynote speaker? 21:47 For me, it's just such an honor to share my learnings as an entrepreneur, as an executive with the world. I still am in this phase where when I give a keynote or moderate a panel, it doesn't really feel like a real thing. It just feels like another discussion for me. That's just kind of my style. I just think that the world stays connected by sharing information like that. And for me, 22:16 I'm lucky to be at the convergence of 20 years of Criteria's product, helping people make hiring decisions and this once in a lifetime emergence of generative AI intersecting with our workforce skills. So I talk a lot about that. Of course, I'm building my own teams to build the Criteria software and platform. 22:42 So I'm also thinking about what is next for my team, how do I upscale and enable? And then of course I'm talking to our thousands of customers on a regular basis trying to make sure that we are leaders in the industry. those are areas I really love talking about. I'm an engineer at heart as well. So I tend to be quite good at bridging kind of the commercial and business side with like core engineering. So I have a deep background in 23:11 AI and ML um even more traditionally prior to the generative AI boom and now even more so post generative AI boom. We're applying generative AI in ways that um we are on the frontier fine tuning models for our uh really predictive models at criteria. So those are all areas I love to talk about and it's really an honor to be able to share that with people no matter the forum. Well maybe there'll be a podcast episode two with Chris on this. 23:41 What about, you you love to share, I don't know where you find the time. You've recently started a nonprofit, the SoCal Tech Forum. So share with my audience the types of activities, where's the venue, who is gathered, and what made you start a nonprofit, right? Yeah, it's a great question. I didn't know I would be starting a nonprofit either, but that tends to be how these things go. 24:11 It's been just a journey. ah We started off as a meetup group. my goal for the meetup group was in the Inland Empire specifically here in Southern California, we don't have many tech meetups. I'm of course networked well in Orange County and Los Angeles. And I think that particularly with these technologies that are 24:35 in our day-to-day life, it's very important that we build community around information and knowledge sharing so we can all learn and get up to speed on AI. A lot of business owners are going through transitions with their workforce, with their team that just were never really imagined. for us, we started this meetup group in the Inland Empire because there was definitely a market gap in getting together. I started off 25:02 paying for and hosting the events, breakfast, etc. And we had so much good interest. had sponsors that decided to volunteer to support, starting with a company called Clutch Coffee and Rancho Cucamonga, who has a deep history of roasting coffee and brewing technology in Rancho. And uh we've since got some other great partners to support us. And in just a little under two years, we've... 25:30 surpassed 750 members in the group. uh that was the reason once we started getting sponsors involved that it made sense to have a 501c3 nonprofit formed. And we have a leadership board now, which I'm really proud of. And we host an event at least once every month on the first Saturday of every month. And they're always technology or technology adjacent topics. They always involve. 25:56 technical and non-technical folks, business owners, entrepreneurs, startups. yeah, it's been really fun. Again, an opportunity to funnel and give back to the community and teach people about disruptive technologies. Well, you heard it here on the Founder's Sandbox, the SoCal Tech Forum. It will be in the show notes, all right, how to um get involved and perhaps attend one of those Saturday meetings. um I wanted to give you an opportunity. 26:25 to provide how people can best contact you, either for speaking opportunities, a CTO of Criteria, the nonprofit. How is it best to contact you, Chris? Yeah, I'd love to hear from you. So you can contact me on LinkedIn. So linkedin.com slash in slash Chris Dayden. All one word. And you can learn more about me as a speaker or CTO of Criteria at chrissdayden.com. excellent. 26:56 have that in the show notes. All right, I want to bring you back to the Founders Sandbox, all right, which is the platform and the podcast. I really get excited about um this part of the podcast. um I work with my clients on resiliency, um scalability, and purpose-driven, right? All with great corporate governance. I always like to ask my guests what... 27:24 the meaning of each of those three words has for them. And each of my guests has a different oh interpretation. And it's just a lot of fun to listen to what I resiliency, what's resiliency for you? I think it's appropriate that I answer that in light of kind of work 4.0. So for me, when it comes to resiliency in work 4.0, um it's about the art of constantly reinventing yourself. 27:53 but in faster cycles. And I think what's really important to everyone is that in Work 4.0, hard skills can become obsolete quicker than before. And that reinvention is critical to really being resilient in this new market. How about scalable? You've scaled a couple of companies, you've been an aqua hire. What does scalable mean to you, Chris? In Work 4.0, scalable will mean 28:22 adequately augmenting the talent you have in humans in your organization with the ability to harness the true power of AI and to do that without losing culture or trust. I think many organizations think of the first half of that. Very few of the organizations can execute on human plus agentic AI and also maintain trust. 28:51 and without losing culture. Have you seen any best practices? This is a little bit off script in terms of companies that have, or are scaling, right? Because this is just scaling pretty quickly in the last year or so. Sure. And are there any best practices out there in building that trust? Yeah, I think having a real holistic AI strategy is key. 29:18 One main component of a holistic AI strategy is how can you get tools to the fingertips of every staff member in your organization so that it's embedded in their workflow? Because a lot of the top-down AI strategy from organizations, like a CEO says, you must use AI and we must be 25 % more efficient, is really shallow when it comes to strategy. And it very rarely results in a culture 29:48 sustaining in a company for this AI growth and augmentation. So what I've been really impressed by is, you know, when I host things like AI monthly global office hours at Criteria, or I host one-on-one sessions with employees to learn about how they're using AI, because you're able to push those tools down to your team members and let them use it in a safe and comfortable area, it allows you to see what people creatively do with AI. And most of the time, 30:17 I could say there's probably 60 or 70 % of use cases that I would never have expected my staff to use AI for, and I would have been the bottleneck of creating if they were waiting for me to do it, and instead give them a safe experimentation zone. And I think that is key to a sustaining AI strategy for So your best practice is actually a criteria from what I'm hearing here. And it's very becoming because I'd like to talk about playfulness in the sandbox, right? 30:46 I read recently, was an EY um study, I think it was this last week, that about 40 % of employees that are forced to use AI tools give up after a month. They don't see the utility in their day-to-day tasks they're doing. So there is something to what you just said, building trust, but building it from the bottom up, right? Yeah, I resonate with that for sure. And I think the only way people break that barrier 31:16 is by seeing their colleagues successful with it. Very rarely is a demo from an executive leader going to be, I mean, it might be enough to begin a culture of AI. Like I had to do a lot of demos and show people kind of the art of the possible. And then as soon as I saw pockets of AI intelligence in the organization, the quicker you can elevate those people to lead and present their findings, the faster... 31:45 you build up kind of the natural human competition between your team and everybody all of a sudden will get more behind it. And that's really important. I think you've reached a point of success in your AI strategy when you were once leading the AI learning sessions and now you are not. How cool is that? You heard it here in the founder sandbox. All right. Purpose driven. What's a purpose driven enterprise for you? I think that 32:12 This is timely based on our discussion just now where organizations need to harness AI at the right times. think purpose for criteria, for example, means how do we measure talent signals that are able to give us the best candidate blueprint or the best candidate DNA possible? And for us, 32:40 every single day, regardless of the technology, what fuels us is having that purpose-driven statement of collecting talent signals around the world for any team. And you really do get lost in that sometimes, for good and for worse, when you're just trying to collect as many talent signals as you can. And being purpose-driven means always doing the right thing when it comes to that. 33:09 mission statement that you've set. And for us, it's collecting talent signals. I think that AI can do that well in a lot of areas, but AI can also be very dangerous in those areas. So when it comes to Work 4.0, having that purpose-driven enterprise statement is very, very important because it anchors us for our new product development. It anchors us for how we're using new technology to help people make the best teams. 33:39 Going back to that, to build the trust, we might clip this out, um does criteria maintain a group of scientists to actually peel back the layers and make meaning out of the signals that you are capturing to create new signals? That's one question. The second is, does criteria have an ethicist on board? 34:08 on call or how do you ensure there is guardrails around talent signals? Yeah, those are really great questions. think for criteria, when we say we're rooted in science, it wouldn't mean very much if it was just a bunch of engineers and product managers kind of deciding what science is, right? So for us, we take a lot of pride in our product IO psychology team. So a lot of them are 34:37 industrial organizational psychologists by trade that are working full time for criteria. And their role is assessment development, assessment validation. uh And particularly in the light of fine tuning AI models, they are very, very hands on in creation of those models, validating those models. There's a lot of legislation we have to comply with, not only the normal data privacy stuff like GDPR and CCPA, but also 35:07 industry specific laws like the New York bias laws and others that help protect uh candidates as they are applying for roles. So that is very, very near and dear to our heart. And also we conduct adverse impact studies and we do case studies with customers to make sure that the product is uh behaving the way that they intended to behave. 35:32 You know, we've got norms for all of our assessments and we adjust those norms based on massive populations of data. So all of that is how we ensure scientific signal. This is amazing. Last question. Did you have fun in the Founder Sandbox today, Chris? I had a lot of fun in the Founder Sandbox. Really a pleasure. Thank you for having me. Thank you, Chris. So to my listeners, if you like this episode with the CTO of Criteria, Chris Daden. 36:02 Sign up for the monthly release for more podcasts where I have business owners, professional service providers, and corporate board directors who are all working to build with strong governance, resilience, scalable, and purpose-driven companies. Thank you. Signing off.

Crash DMs for Beth, Ellie, Io, & Jen. This session: The Second Chances continue to fight the swarm of mindless burning skeletons made of nanites formerly controlled by a lich. Follow this series on… ▶RSS: https://aaronbsmith.com/cogwheel/tag/cause-and-effect/feed/ ▶Patreon: https://www.patreon.com/cogwheelgaming ▶Mastodon: https://is.aaronbsmith.com/@cogwheel Not on Mastodon? Consider these instances: gamepad.club dice.camp mastodon.art chirp.enworld.org tabletop.vip MP3 Download: Cause & … Continue reading "Cause & Effect Ep 69: Everything Dies"

Margaret continues talking with Io about the Iceni revolt of 61 AD that almost drove Rome out of Britain. Sources: https://www.jstor.org/stable/4434717 https://ul.qucosa.de/api/qucosa%3A31804/attachment/ATT-0/ https://web.archive.org/web/20120612044230/http://www.britarch.ac.uk/ba/ba83/feat3.shtml https://penelope.uchicago.edu/Thayer/E/Roman/Texts/Cassius_Dio/62*.html#2 https://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.02.0078%3Abook%3D14%3Achapter%3D32 https://historyandarchaeologyonline.com/the-evidence-for-the-historical-boudica%ef%bf%bc%ef%bf%bc/ https://vridar.org/2018/05/07/doing-history-how-do-we-know-queen-boadicea-boudicca-existed/ https://www.jstor.org/stable/25471937 http://simoneparrish.com/2016/07/how-i-woad-using-woad-for-body-painting/See omnystudio.com/listener for privacy information.

Margherita, 26 anni, cresce a Cutrofiano in una famiglia dove i soldi “non mancano” ma si nominano a bassa voce. Dal padre, ingegnere informatico salito per gradi dalle radici contadine, eredita una bussola severa: ogni spesa è una responsabilità. «Per molti spendere è libertà o espressione. Io invece—anche da bambina—ci pensavo mille volte prima di farlo». Studia Economia a Ferrara, si laurea con il massimo dei voti, poi la magistrale in Marketing a Torino: sempre in pari, mai un “colpo a vuoto”. In testa, un obiettivo chiaro: far sì che le spese sostenute dai genitori durino il meno possibile.Poi, finita l'università, la promessa del merito si sgonfia. «Avevo già dato tutto nello studio. Ero pronta a mostrare ciò che avevo imparato e a diventare indipendente. Ma non è stato così semplice». Torna in Puglia, torna in famiglia, torna l'ansia di “pesare”. I dati lo confermano: a due anni dal titolo, la disoccupazione tra i neolaureati resta intorno al 9–11%. «Non si parla abbastanza di quanto sia difficile il passaggio dall'università al lavoro», dice. Dopo centinaia di candidature, trova un posto nel marketing: prima stage da 700 euro al mese, poi apprendistato triennale da 1.200. I conti tornano perché vive a Gallipoli in una casa dei genitori, ma il lavoro non è quello che immaginava: «Mi sentivo regredita sotto ogni punto di vista… Non era la carriera da film che avevo pensato».L'overqualification logora fiducia e portafogli. Finché il padre le suggerisce ciò che lei non avrebbe osato: un master. Margherita fa i conti e capisce che con i risparmi dei primi due anni può coprire l'affitto a Roma, mentre per la retta ricorre a un prestito d'onore.È l'ennesima spesa “per studiare”, ma anche un tentativo di riallineare desideri e realtà, paura e ambizione. «Mi sento in colpa, ma sapere che i miei non stanno sacrificando nulla mi alleggerisce. Se dovesse andare male, ho tutta la vita per poter recuperare i soldi spesi». La sua storia parla di una generazione che paga—in tempo e denaro—il pedaggio tra laurea e lavoro. Dove l'educazione all'autonomia è anche imparare quando investire ancora su di sé.

Margaret talks with Io about the Iceni revolt of 61 AD that almost drove Rome out of Britain. Sources: https://www.jstor.org/stable/4434717 https://ul.qucosa.de/api/qucosa%3A31804/attachment/ATT-0/ https://web.archive.org/web/20120612044230/http://www.britarch.ac.uk/ba/ba83/feat3.shtml https://penelope.uchicago.edu/Thayer/E/Roman/Texts/Cassius_Dio/62*.html#2 https://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.02.0078%3Abook%3D14%3Achapter%3D32 https://historyandarchaeologyonline.com/the-evidence-for-the-historical-boudica%ef%bf%bc%ef%bf%bc/ https://vridar.org/2018/05/07/doing-history-how-do-we-know-queen-boadicea-boudicca-existed/ https://www.jstor.org/stable/25471937 http://simoneparrish.com/2016/07/how-i-woad-using-woad-for-body-painting/See omnystudio.com/listener for privacy information.

In this episode, we welcome cinematographer Kira Kelly, ASC. Kira has shot projects including Him, 13th, “The Red Line,” “Queen Sugar,” and Rez Ball. In our chat, she shares about her formative years, filmmaking education, and work on the new Jordan Peele-produced movie, Him. Kira also offers extensive cinematography insights and practical advice for emerging filmmakers and industry pros everywhere.“The Making Of” is presented by AJA:UDC-4K: More than just an average 12G-SDI and HDMI up/down/cross converterAJA's newest Mini-Converter boasts powerful 12G-SDI and HDMI 2.0 I/O, 4K/UltraHD/2K/HD scaling, frame sync, frame rate conversion, and more. Unlocking an expansive range of conversion possibilities, UDC-4K enables teams to get disparate sources into a common format and timing reference. Explore how UDC-4K solves some of the most common production and post challenges.Shoot. Store. Secure. Smile.The OWC Guardian is a bus‑powered, portable NVMe SSD featuring 256‑bit AES OPAL hardware encryption and a color touch‑screen for intuitive, secure access. With up to 1,000 MB/s real‑world transfer speeds, platform‑agnostic operation (Mac, PC, iPad Pro), and a rugged anodized aluminum enclosure, it's built to protect audit‑sensitive media and projects anytime, anywhere. Learn more hereAmerican Film Market (AFM)Nov. 11-16, 2025 • Los AngelesAFM is the premier film acquisition, development and networking event where more than $1 Billion in distribution and film financing deals are closed each year on completed films and those in every stage of development. More business-oriented than any other motion picture event, thousands of professionals from all corners of our industry come together at AFM to develop, showcase, discover, finance and license 1000s of independent films and projects destined for the world's audiences.Learn more hereWomen in Media — Holiday Toast 2025Dec 6th | 10am – 2pmHotel Sofitel | Beverly Hills, CAJoin Women In Media as we raise a glass to legendary women of the entertainment industry. There will be a champagne brunch, silent auction, panel with honorees, and celebratory toasts by their toastmasters. Holiday Toast 2025 Honorees include Ashley Nicole Black, Writer/Actor (Shrinking, Ted Lasso, A Black Lady Sketch Show), Toastmaster Chelsea Devantez, Comedian, Writer (The Problem with John Stewart, Girls5Eva), Krystina Figg, Best Boy Grip, Grip (Superman, Killers of the Flower Moon, Dunkirk), and Mandy Walker, AM, ACS, ASC, Director of Photography (Elvis, Hidden Figures, Mulan), President of the American Society of Cinematographers.Get tickets and tables hereMeet Stream Deck Studio:Meet Stream Deck Studio, the ultimate control surface designed for professional broadcast and live production environments. Built on the iconic Elgato hardware and powered by Bitfocus software, it offers a hyper-customizable experience that simplifies even the most complex workflows. With compatibility across hundreds of devices from the industry's top vendors, Stream Deck Studio gives you complete command over your production setup, making it easier than ever to create seamless, high-quality broadcasts. Call Videoguys at 800-323-2325 to learn more and take your production control to the next level today! Explore herePodcast Rewind:Nov. 2025 - Ep. 102…Advertise in “The Making Of” and reach 250K filmmakers, TV production pros, and content creators each week. For more info, email mvalinsky@me.com Get full access to The Making Of at themakingof.substack.com/subscribe

Non solo "Mi chiamo...". Impara tante altre espressioni avanzate per presentarti in modo naturale e come un vero madrelingua. Questa lezione è organizzata in modo progressivo: prima di tutto, vedremo come iniziare una conversazione e presentarsi in modo sofisticato e naturale; poi ci occuperemo di dire il proprio nome con varianti avanzate; successivamente impareremo a parlare della propria provenienza e dei propri interessi. Come Presentarsi in Modo Naturale: oltre il semplice "Ciao, io sono..." 1. Come iniziare una presentazione in modo sofisticato Invece di dire semplicemente "Ciao, io sono...", prova queste alternative più raffinate che dimostrano un livello linguistico superiore: "Non credo che ci siamo mai incontrati prima" - Questa frase elegante introduce la presentazione in modo cortese e naturale, suggerendo che desideri conoscere meglio l'interlocutore. "Non sono sicuro/a che ci abbiano già presentati" - Un'espressione formale perfetta per contesti professionali o sociali dove potreste avere conoscenze comuni ma non vi siete mai parlati direttamente. "Mi sembra che non ci conosciamo ancora" - Una formula di cortesia introduttiva meno formale ma comunque sofisticata, ideale per eventi sociali o situazioni semi-formali. Queste frasi sono perfette quando sei abbastanza sicuro di non aver mai incontrato quella persona prima. Sono formule di cortesia introduttive che dimostrano educazione e padronanza della lingua italiana a livello avanzato. Presentare qualcun altro con eleganza Se vuoi presentare qualcun altro, puoi utilizzare diverse espressioni a seconda del livello di formalità richiesto: "Vorrei presentarti il mio collega, Marco Rossi" - Questa formula è più formale e appropriata per contesti professionali, meeting aziendali o situazioni dove si richiede un certo decoro. "Hai mai conosciuto Giulia? È una mia amica dell'università" - Questa variante è meno formale e più adatta a situazioni sociali rilassate, aperitivi con amici o eventi informali dove il tono può essere più casual. La scelta tra queste due opzioni dipende dal contesto: analizza sempre l'ambiente in cui ti trovi e il rapporto che hai con le persone coinvolte nella presentazione. Ricorda che in Italia il contesto sociale determina fortemente il registro linguistico appropriato. 2. Dire il proprio nome con stile e personalità Va benissimo dire "Io sono Lucia", ma puoi espandere la presentazione in modo più interessante e naturale, soprattutto se usi una versione abbreviata del tuo nome o hai un soprannome. Ecco alcune formule avanzate che i madrelingua usano frequentemente: "Io sono Alessandra, ma tutti mi chiamano Ale" - Questa struttura è perfetta per introdurre immediatamente il nome con cui preferisci essere chiamato, evitando confusioni future e creando un'atmosfera più amichevole. "Il mio nome è Roberto, ma di solito tutti usano Roby" - Una variante leggermente più formale che comunica lo stesso concetto, indicando che il soprannome è comunemente accettato e utilizzato nel tuo ambiente sociale. "Chiamami pure Lina, è il diminutivo di Carolina" - Questa formula esplicita direttamente il tuo desiderio di informalità e spiega anche l'origine del soprannome, cosa molto apprezzata nella cultura italiana. "Il mio nome di battesimo è Bartolomeo, ma solo mia nonna mi chiama così! Mi sono sempre sentito più un Meo" - Un esempio più elaborato che aggiunge un tocco personale e umoristico, creando immediatamente una connessione più intima con l'interlocutore. Aggiungere un tocco di umorismo Gli italiani apprezzano molto l'ironia e l'autoironia nelle presentazioni. Puoi anche aggiungere un tocco scherzoso quando presenti il tuo nome, cosa che rende la conversazione più rilassata e memorabile: "Chiamami come ti pare: Guglielmo, Elmo, Guglie, ma mai Mimmo!" Questo tipo di presentazione dimostra sicurezza, personalità e capacità di usare l'italiano in modo cre...

# James Webb Space Telescope Reveals Cosmic Wonders in Latest "Space Cowboy" PodcastJourney through the cosmos with The Space Cowboy's latest episode exploring groundbreaking James Webb Space Telescope discoveries. From mysterious supermassive black holes to potential building blocks of life, this expert-guided tour reveals JWST's most fascinating recent findings in accessible, engaging detail.The episode covers remarkable discoveries including "BiRD" (a massive black hole from cosmic noon), complex organic molecules in the Large Magellanic Cloud, Jupiter's volcanic moon Io, rogue planets experiencing accretion bursts, interstellar comets, and possible "black hole stars." Perfect for astronomy enthusiasts and anyone fascinated by our universe's deepest mysteries.Subscribe now to stay updated on the latest JWST revelations as The Space Cowboy breaks down cutting-edge space science with expert knowledge and accessible explanations. #JWST #Astronomy #SpaceExploration #CosmicDiscoveriesSome great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Every five years, resuscitation guidelines get a refresh. This year, a few have changed, many have stayed the same, and some are creating major controversy.In this episode, Dr. Ashish Panchal, Chair of the AHA Emergency Cardiovascular Care Committee, helps us unpack what's new, what might surprise you, and the science behind each decision. You'll learn why there's serious debate around epinephrine dosing, what changes matter most for the bedside, and how these updates will change the way you and your team respond to the next code!Topics discussed in this episode:The history and development of the AHA Resuscitation GuidelinesKey improvements: algorithms, clear language, and unified careBig, fundamental changes in the guidelinesHow choking management guidelines have changedThe recommended approach for synchronized cardioversionNew guidelines for post-resuscitation careWhy there's controversy around mechanical CPR and DSDIV vs. IO access: best practice and key takeawaysThe controversy around epinephrine dosingWhat these changes mean for nurses and code teamsListen to E140 with Dr. Ashish Panchal:https://healthpodcastnetwork.com/episodes/rapid-response-rn/140-resuscitation-then-and-now-how-evidence-shapes-every-beat-with-guest-dr-ashish-panchal-md-phd/Mentioned in this episode:AND If you are planning to sit for your CCRN and would like to take the Critical Care Academy CCRN prep course you can visit https://www.ccrnacademy.com and use coupon code RAPID10 to get 10% off the cost of the course!CONNECT

The Italian verb venire (to come) pops up all the time in Italian. See how to use it in the present, past and future tenses. Learn about our Online Italian School and get a free mini lesson every week: https://joyoflanguages.online/italian-school Subscribe to our new YouTube channel: https://www.youtube.com/@joyoflanguages.italian?sub_confirmation=1 Get the bonus materials for this episode: https://italian.joyoflanguages.com/podcast/Italian-verb-venire Today's Italian words: Io e mia mamma veniamo in stazione = My mum and I are coming to the station Ma viene anche mia sorella! = But my sister is also coming! Ma se venite in macchina c'è traffico = But if you (plural) come by car there's traffic Vengo in metro: è comoda = I'm coming by metro: it's convenient

Right on the heels of the release of the 2025 AHA guidelines, including one on preferentially using IVs over IOs, comes two RCTs in the same edition of NEJM that compare intial attempts with IVs to IOs in out of hospital cardiac arrest. Dr Jarvis discusses these two papers while answer a listeners question, and tries to put this, and early epinephrine, into context. And he might throw in some commentary about the AHA's recommendations on mCPR and Heads Up CPR.Citations:1. Couper K, Ji C, Deakin CD, et al. A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2025;392(4):336-348. doi:10.1056/NEJMoa24077802. Vallentin MF, Granfeldt A, Klitgaard TL, et al. Intraosseous or Intravenous Vascular Access for Out-of-Hospital Cardiac Arrest. N Engl J Med. 2025;392(4):349-360. doi:10.1056/NEJMoa2407616

Factories don't run on magic. They run on control panels that turn raw sensor data into precise, safe action—and we're kicking off a three‑part series to show exactly how. We break down the essentials in plain language so you can open a panel door and actually know what you're seeing, from the disconnect and power supplies to the PLC logic and the HMI screens operators trust.We start with the PLC, the rugged brain that reads inputs, executes logic, and drives outputs with millisecond timing. You'll learn why modern controllers are networked, how modular I/O scales with your process, and what clean wiring and accurate channel maps do for uptime. Then we shift to the HMI, the operator window into the process. A well‑built screen mirrors the machine, makes status obvious, and keeps routine actions outside the enclosure for safer work. Clear colors, readable values, trends, and alarms turn data into smart, fast decisions.Power is the quiet foundation. We walk through the pathway: visible disconnects, fuses and breakers sized for protection, control transformers that step down voltage, and 24 VDC power supplies that feed sensors, relays, and PLC cards. Grounding, spacing, and heat management guard both people and electronics. Along the way, we share practical tips to read a panel like a map: trace power first, find the PLC and I/O, compare HMI values to the machine, and rely on current drawings stored on the door. These habits, backed by UL 508A and NFPA 79 principles, create safer, more reliable systems that technicians can troubleshoot under pressure.With nearly a century of experience supporting automation across industries, we believe craftsmanship and documentation are force multipliers. If you're new to automation, mentoring someone who is, or just want a refresher, this guide will raise your confidence on the plant floor. Subscribe for the next parts of the series, share this with a colleague who needs it, and leave a quick review to help more pros find the show.Keep Asking Why...Read our latest article on Industrial Manufacturing herehttps://eecoonline.com/inspire/panels_101 Online Account Registration:Video Explanation of Registering for an AccountRegister for an AccountOther Resources to help with your journey:Installed Asset Analysis SupportSystem Planning SupportSchedule your Visit to a Lab in North or South CarolinaSchedule your Visit to a Lab in VirginiaSubmit your questions and feedback to: podcast@eecoaskwhy.comFollow EECO on LinkedInHost: Chris Grainger

From maintaining aircraft records to dealing with bad advice and sub-standard parts, Mike, Paul, and Colleen say being an aircraft owner is one of the hardest jobs in aviation. Email your questions to podcasts@aopa.org for a chance to get on the show. Join the world's largest aviation community at aopa.org/join Full notes below: Randy wants to know if circuit breakers have a life limit. He has a Mooney with about 3,000 hours. He had one that was acting up, and was wondering if he should intentionally exercise or change them on some interval. Paul said he recommends to all his clients that they exercise their breakers every few years, since they do tend to corrode. Just tripping it breaks oxidation off the contacts, he said. If you check the resistance before and after the resistance often goes down. Colleen said she replaces a few breakers during each annual.   Gary owns a Lake Amphibian with a IO-360 and he runs with fine wire plugs. At the last annual he found four of his Champion plugs had infinite resistance. They otherwise seemed to function normally. He's wondering what the implications are? Paul said he has boxes old boxes of new Champion plugs that he can't force himself to throw away, but he refuses to give them away either because he doesn't trust them. The hosts said they've seen many problems with Champion fire wire plugs and the insulators. So they've stopped using them and suggest others do as well. They all endorse the massive electrode Champions are just fine, however.   Chris helps clients establish aircraft logbooks after they buy their first airplane. Paul said: You should keep as much of the maintenance records as possible for value. Old invoices he puts in a bag and sets them aside. He keeps weight and balance history and it's nice to have a 337 record. Only the current equipment list is necessary. He'll recommend customers organize their own logbooks and not pay him to do it. Colleen also keeps a separate spreadsheet for time in service of all the airplane's components. That makes it easy for inspection, replacement, and for ADs. Mike's records include a big Word doc that includes all his maintenance records and a spreadsheet with the weight and balance, equipment list, and so on. Paul suggests only giving your maintenance provider a thumb drive so they can't hold your logbooks hostage, nor do anything else you don't approve of. Then when you're ready to leave, you get the thumb drive and the sticker to go in the logbook when you get home.   Paul read an article that advised against leaning too quickly and leading to washboarding of cylinders. Mike thinks that came from an old service bulletin. He said it needs to be taken in context. They were talking about heating the cylinder too fast. They weren't talking about the transition from rich of peak to lean of peak, but rather a very rich mixture to a slightly less rich mixture. The piston heats faster than the cylinder barrel, and it expands faster than the cylinder. The piston could potentially cause metal to metal contact.